(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 February 2021 (11.02.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/026447 A1

(51) International Patent Classification:
*A61K 31/445* (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:
PCT/US2020/045392

(22) International Filing Date:
07 August 2020 (07.08.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/883,756 07 August 2019 (07.08.2019) US
62/986,297 06 March 2020 (06.03.2020) US

(71) Applicant: **AMICUS THERAPEUTICS, INC.** [US/US]; 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(72) Inventors: **BENJAMIN, Elfrida**; Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). **WU, Xiaoyang**; Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US).

(74) Agent: **ALEGRIA, Rory P.**; Servilla Whitney LLC, 33 Wood Avenue South, Suite 830, Iselin, New Jersey 08830 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2021/026447 A1

(54) Title: METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE





FIG. 4A

(57) Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing alpha-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for alpha-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding alpha-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

*[Continued on next page]*

**Published:**

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*